These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 11855881

  • 1. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
    Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K.
    Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
    [Abstract] [Full Text] [Related]

  • 2. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF.
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
    [Abstract] [Full Text] [Related]

  • 3. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.
    J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
    [Abstract] [Full Text] [Related]

  • 4. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
    Sasada S, Hirashima T, Nakamura Y, Takimoto T, Furukawa M, Kobayashi M, Nitta T, Matsui K, Kawase I.
    Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
    [Abstract] [Full Text] [Related]

  • 5. Single-dose dexamethasone paclitaxel premedication.
    Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV.
    Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
    [Abstract] [Full Text] [Related]

  • 6. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF.
    Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
    [Abstract] [Full Text] [Related]

  • 7. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
    Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK.
    Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
    [Abstract] [Full Text] [Related]

  • 8. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
    Kobierski J, Majdak E, Mielcarek P, Emerich J.
    Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
    [Abstract] [Full Text] [Related]

  • 9. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
    Slichenmyer WJ, Donehower RC, Chen TL, Bowling MK, McGuire WP, Rowinsky EK.
    Cancer Chemother Pharmacol; 1995 Nov; 36(3):227-32. PubMed ID: 7781143
    [Abstract] [Full Text] [Related]

  • 10. Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions.
    Del Priore G, Smith P, Warshal DP, Dubeshter B, Angel C.
    Gynecol Oncol; 1995 Feb; 56(2):316-8. PubMed ID: 7896206
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Premedication strategy for weekly paclitaxel.
    Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D.
    Cancer Invest; 2002 Feb; 20(5-6):666-72. PubMed ID: 12197222
    [Abstract] [Full Text] [Related]

  • 13. Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
    Yanaranop M, Chaithongwongwatthana S.
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):289-99. PubMed ID: 27098551
    [Abstract] [Full Text] [Related]

  • 14. [Weekly administration of low-dose paclitaxel for advanced or metastatic breast cancer].
    Uno Y, Hirano M, Murakami N, Kikuchi T, Nozawa H, Okuda T, Oya J, Kikkawa H.
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):227-32. PubMed ID: 11865628
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel premedication regimens.
    Boehm DK, Maksymiuk AW.
    J Natl Cancer Inst; 1996 Apr 03; 88(7):463-5. PubMed ID: 8618242
    [No Abstract] [Full Text] [Related]

  • 16. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
    Köppler H, Heymanns J, Weide R.
    Onkologie; 2001 Jun 03; 24(3):283-5. PubMed ID: 11455223
    [Abstract] [Full Text] [Related]

  • 17. Prophylaxis for paclitaxel hypersensitivity reactions.
    Kintzel PE.
    Ann Pharmacother; 2001 Sep 03; 35(9):1114-7. PubMed ID: 11573863
    [Abstract] [Full Text] [Related]

  • 18. [Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
    Kumagai M, Fujii T, Komatsu M, Kusuda T, Takehara K, Shinkou S, Naitou H.
    Gan To Kagaku Ryoho; 2004 Apr 03; 31(4):555-9. PubMed ID: 15114699
    [Abstract] [Full Text] [Related]

  • 19. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
    Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N.
    Clin Cancer Res; 1995 Jun 03; 1(6):599-606. PubMed ID: 9816021
    [Abstract] [Full Text] [Related]

  • 20. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec 03; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.